CFAS Annual Meeting

Westcoast Nurses Education Day

Chan Centre at CFRI
950 West 28th Ave
Vancouver, BC V5Z 4H4
Entrance #18 (Oak Street)

The CFAS Nurses Special Interest Group welcomes you to come and participate in an educational day inspired by feedback from “your wants and needs” survey.

Speakers will be discussing various topics such as; Comprehensive Chromosomal Screening, Embryo Development, 3rd party Legal Considerations and Recurrent Pregnancy Loss.

This one day event will be held at the Chan Centre at the BC Children’s Hospital on Friday, April 13th , 2018 from 10:00am to 4:00pm. A light morning snack and lunch will be provided.

Come and connect with your colleagues out west for what is certain to be a day of interesting discussion.

Register Now!

Member Registration*: $25

Non-member Registration: $100

*Members must login to obtain the preferential member’s rate

Learning Objectives

  1. Understand the stages of embryo development as part of fertility nurses’ patient counseling.
  2. Discuss the science and use of Comprehensive Chromosomal Screening (CCS) to help support patients through this treatment option.
  3. Analyze third party reproduction from a legal perspective experienced in managing the complexities of the law around parentage especially those born through assisted reproductive technologies.
  4. Demystify recurrent pregnancy loss including medical strategies and supportive techniques directed at patients experiencing these losses.
Coffee, tea, morning snacks. Please note that food and drinks are not allowed inside the auditorium.

Dr. Salah Abdelgadir is the laboratory director at Olive Fertility Centre. He received a BVSc from the University of Khartoum, followed by post graduate education at Oregon State University where he obtained a MSc and a PhD in endocrine physiology and biochemistry. Subsequently, Dr. Abdelgadir completed a post-doctoral fellowship at the Oregon Health Sciences University where he cloned the aromatase P450 cDNA and studied factors regulating its gene expression in the brain of monkey primates. Dr. Abdelgadir has extensive experience in assisted reproductive procedures and is certified by the American Board of Bioanalysts as a High-complexity Clinical Laboratory Director and by the Canadian Fertility and Andrology Society as a clinical laboratory director in embryology and andrololgy.

()JonHavelockJon Havelock, MD, FRCSC, FACOG

Dr. Havelock completed his Bachelor of Science and Medical Degree at the University of Manitoba and his residency in Obstetrics and Gynecology at the University of Alberta.  He subsequently went on to complete a three-year, American Board Certified fellowship in Reproductive Endocrinology and Infertility at the University of Texas Southwestern Medical Center in Dallas, Texas.  He is Royal College Certified in Obstetrics and Gynecology, and Board Certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility in the USA.

Dr. Havelock has conducted research in the field of reproductive physiology, with expertise in steroid production of the ovary.  He has presented his research at national and international research conferences in both clinical and basic science research.  He has published in numerous scientific and clinical journals, including Biology of Reproduction, Journal of Clinical Endocrinology and Metabolism, Fertility and Sterility, and Human Reproduction.  His main clinical areas of interest are in Polycystic Ovarian Syndrome (PCOS) and Assisted Reproductive Technologies (ART).  He is Clinical Assistant Professor at the University of British Columbia (UBC) and former Subspecialty Residency Program Director of the Gynecologic Reproductive Endocrinology and Infertility program at UBC.

Dr. Havelock is currently a practicing physician at the Pacific Centre for Reproductive Medicine (PCRM).  He is one of the founders, and co-director of PCRM.  Located in Burnaby, British Columbia, PCRM provides comprehensive fertility care, including ART procedures such as in-vitro fertilization (IVF), reproductive endocrine consultation, tubal ligation reversal and vasectomy reversal surgery, obstetrical ultrasound and high-risk maternal-fetal-medicine consultation and early pregnancy screening.

Comprehensive Chromosomal Screening

The evolution of comprehensive chromosomal screening (CCS) of preimplantation embryos has progressed to cytogenetic testing of chromosome number of blastomeres from cleavage stage embryos for a small panel of common aneuploidies, to molecular genetic testing for all autosomes and sex chromosomes from trophectoderm biopsies.  This talk will present the historical progression and biologic rationale for comprehensive chromosomal screening, the deleterious results from earlier CCS technologies, and the risks and benefits of CCS that should be discussed with patients in order for adequate informed consent to occur.

Learning Objectives

  1. Identify the mechanisms of aneuploidy in the human preimplantation embryo
  2. Contrast the cytogenetic vs molecular genetic technologies for Comprehensive Chromosome Screening (CCS)
  3. Describe the clinical evidence, limitations, predictive values and error rates for CCS in 2016
()barbara-findlay-180x180barbara findlay, Q.C

barbara findlay, Q.C. is a queer feminist lawyer in Vancouver who has been doing agreements for children conceived with assisted human technology for more than twenty years.

barbara findlay

()monique-bioMonique Shebbeare, LLB

Monique Shebbeare is a fertility lawyer and wills and estates lawyer in Vancouver, and has practiced law for 13 years.  Monique grew up in Vancouver before doing her undergraduate degree in psychology at McGill and her law degree at the University of Toronto. She became interested in fertility law after she had her own child through donor conception (with the help of Dr. Hudson at the Victoria Fertility Centre) in 2009. In fertility law, she helps clients with sperm/egg/embryo donor agreements for couples and singles, surrogacy agreements, and multi-parent agreements. Among other issues in her wills practice, Monique helps clients with stored sperm, eggs or embryos make sure they have the documents they need in place in case they die with reproductive material still in storage.

()Zara SulemanZara Suleman, LLM

Zara Suleman practices family law exclusively with a focus on fertility law. She is also a certified family law mediator and collaborative law practitioner. Zara has also been actively involved in presenting, training, writing and editing materials on family law issues including “Baby Steps: Assisted Reproductive Technology and the B.C. Family Law Act”, a paper co-authored with barbara findlay, Q.C. for CLEBC (2013).

Zara Suleman

What has Law got to do with it?  Legal Implications and Considerations for Assisted Human Reproduction

The law regulates the provision of reproductive material, through the federal Assisted Human Reproduction Act, and governs who is a ‘parent’ when a child is conceived with donated reproductive material, under the BC Family Law Act.

Every player in the process – a donor, a surrogate, an intended parent – has different legal interests.

Learning Objectives

In this session you will learn:

  • Who owns donated material and controls its use
  • Why known donors and intended parents should have legal contracts and what these cover
  • Who is a legal ‘parent’ of a child born by assisted reproduction
  • Who has to sign what contracts, and when, to make sure that the child has the parents they were intended to have when they are born
  • What things a surrogate should look for in a contract
  • What things intending parents should watch out for
  • What if a client dies with frozen eggs, sperm and embryos in storage

()DSC_8019Carl A. Laskin MD, FRCPC
Managing Director and Deputy Medical Director, TRIO Fertility;
Associate Professor of Medicine and Obstetrics & Gynecology,
University of Toronto

Dr. Carl Laskin obtained his MD from McMaster University in 1975. He completed his training in internal medicine and rheumatology in 1980. From 1980-83, he was a Visiting Fellow in immunology at the National Institutes of Health in Bethesda, Maryland. Since 1983 he has been at the University of Toronto in the Division of Rheumatology in the Department of Medicine with a cross-appointment to the Department of Obstetrics & Gynecology. In 1985, he established the Treatment and Evaluation of Recurrent Miscarriage (TERM Programme), which has continued to date.

Dr. Laskin continues to be actively involved in clinical research dealing with recurrent miscarriage; reproductive medicine in women and men with rheumatic diseases including infertility and pregnancy. He is a frequent speaker at international and national meetings in both rheumatology and obstetrics & gynecology. Dr. Laskin is a founding partner and Managing Partner of TRIO Fertility in Toronto where he is involved in both clinical and research activities dealing with the problem of infertility as well as recurrent miscarriage.

Dr. Laskin is a past president of the Canadian Fertility & Andrology Society and will likely be the only rheumatologist to ever hold that office.

Recurrent Pregnancy Loss: Moving the Yardsticks Down the Field

Fifteen to thirty percent of pregnancies result in early pregnancy losses. This frequency increases with advancing maternal age. Having said this, there are many women in the reproductive age group who suffer with losing 2 or more pregnancies apparently without cause. The accepted causes of recurrent pregnancy loss (RPL) are anatomical, genetic, hormonal and autoimmune. The last category has attracted an inordinate amount of interest over the past 30 years but it has become apparent that the initial excitement must be tempered as it affects fewer than originally anticipated.

The approach to investigation must follow a logical plan. A detailed history and physical exam of the woman and partner should be undertaken. This is followed by anatomical studies in the woman. Karyotypes on both partners must be undertaken. Hormone profile on both partners with a detailed semen analysis on the male partner are part of the initial evaluation. An endometrial biopsy maybe performed to assess for chronic endometritis. Once this is complete and no cause is found, a targeted immune evaluation would then be indicated.

Management is directed to a cause if discovered. If the couple remains idiopathic, then monitoring of a cycle to assess folliculogenesis may be helpful with intervention based upon the findings. In contrast to the opinions of some, IVF with PGS may provide insight into the underlying problem and result in a successful pregnancy.

Learning Objectives

At the end of this session, participants should be able to:

  1. Define the criteria of clinically significant recurrent pregnancy loss
  2. State the known causes of recurrent pregnancy loss
  3. List investigations required for recurrent pregnancy loss in both female and male patients.
  4. Assess management strategies of recurrent pregnancy loss